Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey.

BACKGROUND Infectious complications in febrile neutropenic patients are still major causes of morbidity and mortality despite significant advances in diagnostic techniques and antimicrobial therapy. In this study, we describe the characteristics of patients with hematological malignancies who were evaluated for suspected infection. This study was also conducted to assess the isolation rate of bacterial and fungal causative agents in febrile neutropenic attacks. METHOD The study was conducted at Pamukkale University Hospital, Turkey. In order to identify the characteristics of patients with hematological malignancies in the presence/suspicion of any accompanying infectious disease, patients' charts with hematological malignancies were reviewed for signs/symptoms of any infection between October 1, 2001, and May 31, 2005, retrospectively. RESULTS Overall, 90 infectious episodes occurred in 59 patients. The most common underlying diseases were acute myelogenous leukemia (61.0%) and acute lymphocytic leukemia (15.3%). The absolute neutrophil count was lower than 100/mm(3) in 33 (36.7%) episodes. Microbiologically and clinically documented infections and fever of unknown origin were observed in 35.6%, 28.9%, and 35.6% of the participants, respectively. Bloodstream infections and pneumonia were detected in 21.1% and 18.9% of episodes, respectively. Gram negative organisms were most common (58.4%), followed by gram positive cocci. A combination of third generation cephalosporin and an aminoglycoside were used in 44.4% of episodes initially. Fever resolved in 24.4% of episodes using the initial therapy. The mortality rate was 15.6%. CONCLUSION These results showed that infections with gram-negative bacteria continue to predominate in febrile neutopenic episodes in our center.

[1]  M. Akova Emerging problem pathogens: A review of resistance patterns over time , 2006 .

[2]  R. E. Warren,et al.  Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  S. Harthug,et al.  A multi-centre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility , 2005, Scandinavian journal of infectious diseases.

[4]  N. Çetingül,et al.  Meropenem Plus Amikacin Versus Piperacillin-Tazobactam Plus Netilmicin as Empiric Therapy for High-Risk Febrile Neutropenia in Children , 2004, Pediatric hematology and oncology.

[5]  P. Pizzo,et al.  Management of Infections in Immunocompromised Patients , 2000 .

[6]  J. L. Fuentes-Allen,et al.  Microbiological findings in febrile neutropenia. , 2000, Archives of medical research.

[7]  H. Ariffin,et al.  Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. , 2000, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[8]  E. Kansu,et al.  Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. , 1999, International journal of antimicrobial agents.

[9]  B. Oppenheim The changing pattern of infection in neutropenic patients. , 1998, The Journal of antimicrobial chemotherapy.

[10]  M. Villasís-Keever,et al.  Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure. , 1998, Archives of medical research.

[11]  M. Paesmans,et al.  A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies , 1997, British journal of haematology.

[12]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  G. Donowitz Fever in the compromised host. , 1996, Infectious disease clinics of North America.

[14]  A. Mohar,et al.  Experience of an intravenous therapy team at the Instituto Nacional de Cancerología (Mexico) with a long-lasting, low-cost silastic venous catheter. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[16]  J. Shenep,et al.  Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1991, The Journal of infectious diseases.

[17]  L. Young,et al.  From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1990, The Journal of infectious diseases.

[18]  S. Schimpff Overview of empiric antibiotic therapy for the febrile neutropenic patient. , 1985, Reviews of infectious diseases.

[19]  Jean-Guy Cyr,et al.  Principles and Practice of Infectious Diseases , 1980 .

[20]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.